drugset / Trial / NCT03216876
A Study Of Ursolic Acid For Primary Sclerosing Cholangitis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, active treatment trial to determine the pharmacokinetics of orally administered ursolic acid and to assess the potential efficacy and safety of ursolic acid in subjects with primary sclerosing cholangitis (PSC).
Timeline
- Start
- 2017-09
- Primary completion
- 2019-01
- Completion
- 2019-07
Outcome
Outcome not reported
Stopped: “Lack of feasibility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ursolic Acid | Small molecule | 40 mg | Oral |
| Subject | Ursolic Acid | Small molecule | 80 mg | Oral |
| Subject | Ursolic Acid | Small molecule | 120 mg | Oral |